Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 8/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001809 | 0.93 | DRD4 (0.63) | KDM4ELMNAMAPTDRD4SIGMAR1 | |
| SCHEMBL4001565 | 0.93 | KDM4E (0.63) | KDM4ELMNAMAPTDRD4SIGMAR1 | |
| SCHEMBL4008952 | 0.91 | KMT2A (0.49) | KDM4ELMNAMAPTDRD4SIGMAR1 | |
| SCHEMBL4000378 | 0.91 | DRD4 (0.64) | KDM4ELMNAMAPTDRD4ALDH1A1 | |
| SCHEMBL4007220 | 0.90 | DRD4 (0.62) | KDM4ELMNAMAPTDRD4SIGMAR1 | |
| SCHEMBL4005330 | 0.89 | KMT2A (0.52) | KDM4ELMNAMAPTDRD4SIGMAR1 | |
| SCHEMBL4005094 | 0.88 | DRD4 (0.54) | KDM4ELMNAMAPTDRD4SIGMAR1 | |
| SCHEMBL4007305 | 0.87 | MEN1 (0.55) | KDM4ELMNAMAPTDRD4SIGMAR1 | |
| SCHEMBL4006705 | 0.86 | KDM4E (0.53) | KDM4ELMNAMAPTDRD4ALDH1A1 | |
| SCHEMBL4005384 | 0.85 | DRD4 (0.63) | KDM4EMAPTDRD4ALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | claimed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | claimed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | claimed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | claimed |
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KDM4E 2903/4885LMNA 4331/4885MAPT 3896/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KDM4E 2903/4885LMNA 4331/4885MAPT 3896/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | KDM4E 2613/4885LMNA 4410/4885MAPT 3453/4885 |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KDM4E 2903/4885LMNA 4331/4885MAPT 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.